Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection

JAMA

Volumn 296, Issue 12, 2006, Pages 1488-1497

  Atik, Berna ^a   Thanh, Ton Ton Kim ^b   Luong, Vu Quoc ^b   Lagree, Stephane ^c   Dean, Deborah ^a,d  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b National Institute of Ophthalmology   (Viet Nam)

^c International Trachoma Initiative   (Viet Nam)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BACTERIAL INFECTION; CHILD; CHLAMYDIA TRACHOMATIS; COMMUNITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG COST; FEMALE; HUMAN; IMMUNITY; INCIDENCE; LONGITUDINAL STUDY; MALE; MEDICAL RESEARCH; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REINFECTION; RISK FACTOR; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TRACHOMA; VIET NAM; ADOLESCENT; CLINICAL TRIAL; PRESCHOOL CHILD; RECURRENT DISEASE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; RECURRENCE; TRACHOMA; VIETNAM;

EID: 33749060048     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.12.1488     Document Type: Article

References (46)

1. Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ. 1995;73:115-121.
2. Report of Planning for the Global Elimination of Trachoma (GET). Geneva, Switzerland: World Health Organization; 1996. http://www.who.int/pbd/ publications/trachoma/en/get_1996.pdf. Accessed February 6, 2006.
3. Report of the First Meeting of the WHO Alliance for the Global Elimination of Trachoma. Geneva, Switzerland: World Health Organization; 1997. http://www.who.int/pbd/publications/trachoma/en/get_1997.pdf. Accessed February 6, 2006.
4. Report of the Second Meeting of the WHO Alliance for the Global Elimination of Trachoma. Geneva, Switzerland: World Health Organization; 1998. http://www.who.int/entity/pbd/publications/trachoma/en/get_jan1998.pdf. Accessed February 6, 2006.
5. Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med. 1999;5:572-576.
6. Chidambaram JD, Alemayehu W, Melese M, et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA. 2006;295:1142-1146.
7. Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis. 1997;24:363-368.
8. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet. 1999;354:630-635.
9. Bowman RJ, Sillah A, Van Dehn C, et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest Ophthalmol Vis Sci. 2000;41:4074-4079.
10. Holm SO, Jha HC, Bhatta RC, et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Organ. 2001;79:194-200.
11. Fraser-Hurt N, Bailey RL, Cousens S, Mabey D, Faal H, Mabey DC. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ. 2001;79:632-640.
12. Gaynor BD, Miao Y, Cevallos V, et al. Eliminating trachoma in areas with limited disease. Emerg Infect Dis. 2003;9:596-598.
13. Chidambaram JD. Trachoma decline and wide-spread use of antimicrobial drugs. Emerg Infect Dis. 2004;10:1895-1899.
14. Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med. 2004;351:1962-1971.
15. Melese M, Chidambaram JD, Alemayehu W, et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA. 2004;292:721-725.
16. Braff E, Winkelstein W. Field treatment of trachoma in North Vietnam. Public Health Rep. 1952;67:1233-1236.
17. Nguyen DH. Prevention and treatment of trachoma and the anti-blindness program. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique. 1991;68:171-177.
18. Verin P, Duong DT, Mortemousque B, Dorot N. Cause of blindness in the province of Giang-Vietnam. Int Trach Pathol Ocul Trop Subtrop Sante Publique. 1997;74:57-63.
19. Report of the Fourth Meeting of the WHO Alliance for the Global Elimination of Trachoma. Geneva, Switzerland: World Health Organization; 1999. http://www.who.int/entity/pbd/publications/trachoma/en/get_1999.pdf. Accessed February 6, 2006.
20. Jha H, Chaudary JS, Bhatta R, et al. Disappearance of trachoma from Western Nepal. Clin Infect Dis. 2002;35:765-768.
21. International Trachoma Initiative. SAFE Program in Viet Nam: Detailed Implementation Plan. 2000: 1-23. http://www.trachoma.org/php#cpro. Accessed September 4, 2006.
22. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65:477-483.
23. Zhang H, Kandel RP, Sharma B, Dean D. Risk factors for recurrence of postoperative trichiasis: implications for trachoma blindness prevention. Arch Ophthalmol. 2004;122:511-516.
24. Bailey R, Duong T, Carpenter R, Whittle H, Mabey D. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect. 1999;123:479-486.
25. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 1993;342:453-456.
26. Tabbara KF, Abu-el-Asrar A, al-Omar O, Choudhury AH, al-Faisal Z. Single-dose azithromycin in the treatment of trachoma: a randomized, controlled study. Ophthalmology. 1996;103:842-846.
27. Guzey M, Aslan G, Ozardali I, Basar E, Satici A, Karadede S. Three-day course of oral azithromycin vs topical oxytetracycline/polymyxin in treatment of active endemic trachoma. Jpn J Ophthalmol. 2000;44:387-391.
28. Laming AC, Currie BJ, DiFrancesco M, Taylor HR, Mathews JD. A targeted, single-dose azithromycin strategy for trachoma. Med J Aust. 2000;172:163-166.
29. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis. 2005;192:1836-1844.
30. Taylor HR, Siler JA, Mkocha HA, Munoz B, West S. The natural history of endemic trachoma: a longitudinal study. Am J Trop Med Hyg. 1992;46:552-559.
31. Bailey R, Osmond C, Mabey DC, Whittle HC, Ward ME. Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure. Int J Epidemiol. 1989;18:944-951.
32. Burton MJ, Holland MJ, Faal N, et al. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci. 2003;44:4215-4222.
33. Assaad FA, Sundaresan T, Maxwell-Lyons F. The household pattern of trachoma in Taiwan. Bull World Health Organ. 1971;44:605-615.
34. Frick KD, Lietman TM, Holm SO, Jha HC, Chaudhary JS, Bhatta RC. Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull World Health Organ. 2001;79:201-207.
35. Baral K, Osaki S, Shreshta B, et al. Reliability of clinical diagnosis in identifying infectious trachoma in a low-prevalence area of Nepal. Bull World Health Organ. 1999;77:461-466.
36. Luna EJ, Medina NH, Oliveira MB, et al. Epidemiology of trachoma in Bebedouro State of Sao Paulo, Brazil: prevalence and risk factors. Int J Epidemiol. 1992;21:169-177.
37. UNICEF. Statistics at a glance: Viet Nam. http://www.unicef.org/ infobycountry/vietnam_statistics.html. Accessed July 5 2005.
38. Halloran ME. Concepts of infectious disease epidemiology. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia, Pa: Lippincott Williams & Wilkins; 1998:529-554.
39. United Nations. Population and vital statistics report. http://unstats.un.org/unsd/seriesa/index.asp. Accessed Jan 11, 2006.
40. Dean D. Trachoma. In: Connor DH, Schwartz DA, Chandler FW, eds. Pathology of Infectious Diseases. Stamford, Conn: Appleton & Lange Publishers; 1997:498-507.
41. Wang SP, Grayston JT, Alexander ER. Trachoma vaccine studies in monkeys. Am J Ophthalmol. 1967;63(5 suppl):1615-1630.
42. Taylor HR. Development of immunity to ocular chlamydial infection. Am J Trop Med Hyg. 1990;42:358-364.
43. Taylor HR, Young E, MacDonald AB, Schachter J, Prendergast RA. Oral immunization against chlamydial eye infection. Invest Ophthalmol Vis Sci. 1987;28:249-258.
44. Barsoum IS, Hardin LK, Colley DG. Immune responses of mice after conjunctival exposure to Chlamydia trachomatis serovar A. Med Microbiol Immunol (Berl). 1988;177:349-356.
45. Dean D, Powers VC. Persistent Chlamydia trachomatis infections resist apoptotic stimuli. Infect Immun. 2001;69:2442-2447.
46. Sheffield JS, Andrews WW, Klebanoff MA, et al. Spontaneous resolution of asymptomatic Chlamydia trachomatis in pregnancy. Obstet Gynecol. 2005;105:557-562.